Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668300 · ClinicalTrials.gov registry record · Phase 2
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
A Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04668300: Active Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma, sponsored by M.D. Anderson Cancer Center.
NCT04668300 is a Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 75 participants, above the 61-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (23% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668300, a Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
Defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL Oleclumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-11-26 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT04668300 still lists
NCT04668300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 61-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (23% higher).
The record links to 8 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT04668300 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04668300 about?
NCT04668300 is a clinical study titled "Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma". This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab a...
What is the current status of trial NCT04668300?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2020-11-26. Estimated completion is 2026-06-30.
What conditions does trial NCT04668300 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Metastatic Osteosarcoma, Refractory Osteosarcoma, Metastatic Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma.
What interventions are being tested in trial NCT04668300?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Oleclumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04668300?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04668300 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04668300's enrollment target sits among peer trials
75 5th of 13 higher than 9 of 13 other Recurrent Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
-
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI